Angiotensin-converting enzyme 2 inhibits lung injury induced by respiratory syncytial virus

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Gu, Hongjing ^a   Xie, Zhengde ^b   Li, Tieling ^c   Zhang, Shaogeng ^d   Lai, Chengcai ^a   Zhu, Ping ^a   Wang, Keyu ^a   Han, Lina ^c   Duan, Yueqiang ^a   Zhao, Zhongpeng ^a   Yang, Xiaolan ^a   Xing, Li ^a   Zhang, Peirui ^d   Wang, Zhouhai ^d   Li, Ruisheng ^d   Yu, Jane J ^e   Wang, Xiliang ^a   Yang, Penghui ^a,d  

^a BEIJING INSTITUTE OF MICROBIOLOGY AND EPIDEMIOLOGY   (China)

^b CAPITAL MEDICAL UNIVERSITY   (China)

^c CHINESE PLA GENERAL HOSPITAL   (China)

^d Beijing302 Hospital   (China)

^e UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANGIOTENSIN 2 RECEPTOR; ANGIOTENSIN CONVERTING ENZYME 2; DIPEPTIDYL CARBOXYPEPTIDASE;

ANIMAL; DISEASE MODEL; GENETICS; KNOCKOUT MOUSE; LUNG INJURY; METABOLISM; MOUSE; PATHOLOGY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RESPIRATORY SYNCYTIAL VIRUS INFECTION; SEVERITY OF ILLNESS INDEX; VIROLOGY;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; DISEASE MODELS, ANIMAL; LUNG INJURY; MICE; MICE, KNOCKOUT; PEPTIDYL-DIPEPTIDASE A; RECEPTOR, ANGIOTENSIN, TYPE 1; RECEPTOR, ANGIOTENSIN, TYPE 2; RENIN-ANGIOTENSIN SYSTEM; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; SEVERITY OF ILLNESS INDEX;

EID: 84955512711     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep19840     Document Type: Article

References (30)

1. Waghmare, A. et al. Respiratory syncytial virus lower respiratory disease in hematopoietic cell transplant recipients: Viral RNA detection in blood, antiviral treatment, and clinical outcomes. Clin Infect Dis 57, 1731-41 (2013).
2. Shirey, K. A. et al. Control of RSV-induced lung injury by alternatively activated macrophages is IL-4R alpha-, TLR4-, and IFN-betadependent. Mucosal Immunol 3, 291-300 (2010).
3. Hall, C. B. et al. The burden of respiratory syncytial virus infection in young children. N Engl J Med 360, 588-98 (2009).
4. Papin, J. F. et al. Infant baboons infected with respiratory syncytial virus develop clinical and pathological changes that parallel those of human infants. Am J Physiol Lung Cell Mol Physiol 304, L530-9 (2013).
5. Liesman, R. M. et al. RSV-encoded NS2 promotes epithelial cell shedding and distal airway obstruction. J Clin Invest 124, 2219-33 (2014).
6. Crackower, M. A. et al. Angiotensin-converting enzyme 2 is an essential regulator of heart function. Nature 417, 822-8 (2002).
7. Zhong, J. et al. Angiotensin-converting enzyme 2 suppresses pathological hypertrophy, myocardial fibrosis, and cardiac dysfunction. Circulation 122, 717-28, 18 p following 728 (2010).
8. Oudit, G. Y. et al. Angiotensin II-mediated oxidative stress and inflammation mediate the age-dependent cardiomyopathy in ACE2 null mice. Cardiovasc Res 75, 29-39 (2007).
9. Burrell, L. M., Johnston, C. I., Tikellis, C. & Cooper, M. E. ACE2, a new regulator of the renin-angiotensin system. Trends Endocrinol Metab 15, 166-9 (2004).
10. Imai, Y. et al. Angiotensin-converting enzyme 2 protects from severe acute lung failure. Nature 436, 112-6 (2005).
11. Kuba, K. et al. A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury. Nat Med 11, 875-9 (2005).
12. Zou, Z. et al. Angiotensin-converting enzyme 2 protects from lethal avian influenza A H5N1 infections. Nat Commun 5, 3594 (2014).
13. Hashimoto, T. et al. ACE2 links amino acid malnutrition to microbial ecology and intestinal inflammation. Nature 487, 477-81 (2012).
14. Kuba, K., Imai, Y. & Penninger, J. M. Angiotensin-converting enzyme 2 in lung diseases. Curr Opin Pharmacol 6, 271-6 (2006).
15. Yang, P. et al. Angiotensin-converting enzyme 2 (ACE2) mediates influenza H7N9 virus-induced acute lung injury. Sci Rep 4, 7027 (2014).
16. Olszewska, W. et al. Antiviral and lung protective activity of a novel respiratory syncytial virus fusion inhibitor in a mouse model. Eur Respir J 38, 401-8 (2011).
17. Li, F., Zhu, H., Sun, R., Wei, H. & Tian, Z. Natural killer cells are involved in acute lung immune injury caused by respiratory syncytial virus infection. J Virol 86, 2251-8 (2012).
18. Imai, Y. et al. Identification of oxidative stress and Toll-like receptor 4 signaling as a key pathway of acute lung injury. Cell 133, 235-49 (2008).
19. Kawasaki, Y. et al. Serum SP-D levels as a biomarker of lung injury in respiratory syncytial virus bronchiolitis. Pediatr Pulmonol 46, 18-22 (2011).
20. Kawasaki, Y. et al. Serum KL-6 levels as a biomarker of lung injury in respiratory syncytial virus bronchiolitis. J Med Virol 81, 2104-8 (2009).
21. Hammer, J., Numa, A. & Newth, C. J. Acute respiratory distress syndrome caused by respiratory syncytial virus. Pediatr Pulmonol 23, 176-83 (1997).
22. Huang, F. et al. Angiotensin II plasma levels are linked to disease severity and predict fatal outcomes in H7N9-infected patients. Nat Commun 5, 3595 (2014).
23. Rameix-Welti, M. A. et al. Visualizing the replication of respiratory syncytial virus in cells and in living mice. Nat Commun 5, 5104 (2014).
24. Polack, F. P. et al. A role for immune complexes in enhanced respiratory syncytial virus disease. J Exp Med 196, 859-65 (2002).
25. Chanock, R., Roizman, B. & Myers, R. Recovery from infants with respiratory illness of a virus related to chimpanzee coryza agent (CCA). I. Isolation, properties and characterization. Am J Hyg 66, 281-90 (1957).
26. Kapikian, A. Z. et al. An outbreak of febrile illness and pneumonia associated with respiratory syncytial virus infection. Am J Hyg 74, 234-48 (1961).
27. Moore, M. L. et al. A chimeric A2 strain of respiratory syncytial virus (RSV) with the fusion protein of RSV strain line 19 exhibits enhanced viral load, mucus, and airway dysfunction. J Virol 83, 4185-94 (2009).
28. Smith, D. M. & Waite, M. Phosphatidylinositol hydrolysis by phospholipase A2 and C activities in human peripheral blood neutrophils. J Leukoc Biol 52, 670-8 (1992).
29. Gaddam, R. R., Chambers, S. & Bhatia, M. ACE and ACE2 in inflammation: A tale of two enzymes. Inflamm Allergy Drug Targets 13, 224-34 (2014).
30. Bem, R. A., Domachowske, J. B. & Rosenberg, H. F. Animal models of human respiratory syncytial virus disease. Am J Physiol Lung Cell Mol Physiol 301, L148-56 (2011).